We are leveraging our
knowledge of autophagy
biology to create
Samsara is leveraging its knowledge of new autophagy biology to rapidly advance multiple drug candidates to the clinic – promising new therapies designed to treat serious rare genetic diseases and neurodegenerative disorders with a strong genetic component. These diseases all have limited or no known treatment options.
We focus on identifying novel targets and mechanisms which have a strong genetic linkage to dysfunctional autophagy, and pair this new biology with the appropriate genetically driven disease where autophagy plays a driving role, and where we have generated strong in-house evidence of disease modification.
Samsara Therapeutics adds eminent neurologist Professor Dame Pamela Shaw to its scientific advisory board to help accelerate ALS/MND treatment development
Samsara Therapeutics, the autophagy biotech company, has appointed eminent neurologist and world-leading researcher in Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND) Professor Dame Pamela Shaw to its scientific advisory board.
Samsara Therapeutics announced today that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to further its research into a promising Parkinson’s disease drug.
Samsara Therapeutics unveils promising autophagy drug candidate, offering new hope for people with Parkinson’s and motor neurone disease
Samsara Therapeutics is first in the race to find a viable, potent autophagy inducing drug, with the potential to give us longer and healthier lives.
We caught up with Senior Scientists Gabriela Vilema Enríquez and Matthew Williamson on their work within the neuroscience team at Samsara.